---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-155503"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2025-07-03T23:59:59+00:00"
generated_at: "2026-05-18T09:27:44.686166+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# UroGen awards special bonuses totaling $845K to CEO, CFO, GC for ZUSDURI FDA approval

## Summary
- CEO Elizabeth Barrett receives $645,000; CFO Chris Degnan and GC Jason Smith each get $100,000.
- Bonuses approved June 30, 2025, for leadership leading to FDA approval of ZUSDURI for recurrent low-grade intermediate risk NMIBC.
- ZUSDURI is a novel therapy for non-muscle invasive bladder cancer (NMIBC).
- One-time special awards; no recurrence or changes to base compensation.

## SEC filing metadata
- accession: 0001193125-25-155503
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2025-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312525155503/0001193125-25-155503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312525155503/d941822d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-155503
- JSON: https://secwatch.observer/filing/0001193125-25-155503.json
- Plain text: https://secwatch.observer/filing/0001193125-25-155503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.